Professor Emeritus Christopher R. Lowe, OBE, FREng was originally trained as a biochemist (University of Birmingham) and following postdoctoral positions in Liverpool and Lund (Sweden) and a lectureship at the University of Southampton, he was appointed to the University of Cambridge in 1984 to  found the Institute of Biotechnology, which he ran for 23 years prior to subsequently merging it with the Department of Chemical Engineering in 2008 to form the Department of Chemical Engineering & Biotechnology, which is now based at West Cambridge. He is a Fellow of Trinity College, the Royal Academy of Engineering, the Institute of Physics and a Life Member of the Royal Institution. The principal focus of his research programme has been the healthcare biotechnology sector, particularly in biologics, enzyme and microbial technology and biosensors. He has over 430 peer-reviewed publications, 8 books and monographs, >100 patents and has supervised 99 PhD students. He has won a number of National and International prizes: Pierce Award for Outstanding Contributions to the Field of Affinity Chromatography (1989), David Curnow Prize (Clinical Chemistry)(1991),“Queen’s Award for Technological Achievement (1996)” Jubilee Medal: The Chromatographic Society (2002), Henry Dale Medal, Prize and Life Membership: The Royal Institution (London)(2003), RSC Sensors Silver Medal (2006) and a “Queen’s Anniversary Prize for Higher and Further Education (2007)” and he has the title of “Most Entrepreneurial Scientist of the UK”. He was awarded an OBE in the Queen’s New Year Honours, the title BBSRC Commercial Innovator of the Year in 2011, visiting chair at the Australian National University in Canberra (2016), a visiting “Super-Professor” in Japan (2017) and an Honorary Doctorate from the University of Surrey (2019). He has been the driving force for the establishment of 12 spin-out companies, including Prometic Biosciences Inc, Affinity Sensors Ltd, Cambridge Sensors Ltd, Psynova Neurotech Ltd, Paramata Ltd, Smart Holograms Ltd, TumourVue Ltd, Continuous Diagnostics Ltd and Royale Therapeutics Ltd, is on the Editorial Boards of International Journals, sits on or has sat on a number of UK Research Council and Government committees, multiple International Granting Organisations and is actively engaged in technology transfer and entrepreneurship worldwide. He established the Master’s in Bioscience Enterprise (MBE) in 2002 and the Master’s in Therapeutic Sciences (MTS) in 2018. After formal retirement, he was re-employed by the University to establish the Cambridge Academy of Therapeutic Sciences (CATS) to promote research, translation, education and policy in therapeutic sciences.

ORCID: 0000-0001-5432-9109